key: cord-0749371-9o6h0sly authors: Shapiro, J.; Dean, N. E.; Madewell, Z. J.; Yang, Y.; Halloran, M. E.; Longini, I. M. title: Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports date: 2021-05-21 journal: nan DOI: 10.1101/2021.05.20.21257461 sha: c0c309c487ffc248cb557d928099b4ee81767013 doc_id: 749371 cord_uid: 9o6h0sly In this report, we provide summary estimates, from publications and reports, of vaccine efficacy (VE) for the COVID-19 vaccines that are being rolled out on a global scale. We find that, on average, the efficacy against any disease with infection is 85% (95% CI: 71 - 93%) after a full course of vaccination. The VE against severe disease, hospitalization or death averages close to 100%. The average VE against infection, regardless of symptoms, is 84% (95% CI: 70 - 91%). We also find that the average VE against transmission to others for Infected vaccinated people is 54% (95% CI: 38 - 66%). Finally, we prove summary estimates of the VE against any disease with infection for some of the variants of concern (VOC). The average VE for the VOC B.1.1.7, B.1.1.28 (P1) and B.1.351 are 86% (95% CI: 65 - 84%), 61% (95% CI: 43 - 73%) and 56% (95% CI: 29 - 73%), respectively. In this report, we summarize estimates of vaccine efficacy (VE) for the COVID-19 vaccines that are being rolled out on local and global scales. This includes the Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Sputnik, Novavax, Sinovac, and Sinopharm vaccines. VE estimates are taken from journal articles and media reports for the vaccines that have gone through double-blinded, placebo-controlled, phase III vaccine trials, as well as observational studies. Some of the estimates are based on rigorous, preplanned statistical analyses from double-blinded, placebo-controlled trials, while others are extracted from observational studies with different levels of control. These studies are reported from a variety of sources including publications, reports, and sometimes press releases. Because of this, we do not carry out a formal meta analysis. In all cases, we try to extract estimates for one or more of the triplet of vaccine efficacy parameters (V E S , V E P , V E I ) [1] , where V E S is VE against infection; V E P is VE against disease, given infection; and V E I is VE against transmission to others, given infection. A fourth parameter, V E SP , which is VE against disease and infection, tends to be available from vaccine trials, and it is the usual primary outcome for those trials (i.e., cases of disease that are confirmed infections). The V E SP is a function of both the V E S and V E P . If we believe in a multiplicative and independent relationship, then V E SP = 1-(1 − V E S )(1 − V E P ). Thus, if we have two of these VE's, we can always calculate the third. In the material that follows, we give estimates of these VE's as a function of time when protection is believed to begin to occur after the first and second dose for two-dose vaccines, and after the first dose for one-dose vaccines. We also provide V E SP estimates for protection against the variants of concern (VOC) B.1.1.7, B.1.1.28 (P1) and B.1.351. The methods for creating the forest plots are given in the Appendix. The supporting tables for the analysis are also given in the Appendix. Not all estimates described in the tables are given in the figures, as we have tried to extract the essential information without getting lost in too much detail. However, virtually all the complete information is given in the Appendix tables. The estimated V E SP after one dose, for both two-dose and one-dose vaccines, is given in Figure 2 (Table A2) , where the Johnson & Johnson vaccine is the only one-dose vaccine listed. The estimates are generally almost as high as protection after one dose, with summary estimated of 82% (95% CI: 72 -88%). 3 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (Table A3) give the estimates of the V E S SP (VE for severe disease with infection) after the second dose for two-dose vaccines. The estimates a very high, and generally close to 100%, with relatively poor precision. 4 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (Table A4) give the estimates of the V E S SP (VE for severe disease with infection) after the first dose for two-dose vaccines and one dose for the one-dose vaccine. The summary estimated is quite high at 86% (95% CI: 39 -97%). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2021. ; (Table A7) give the estimates of the V E S , i.e., VE against infection. The estimates were quite high, with a summary estimate of 84% (95% CI: 70 -91%). 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2021. (Table A8) give estimates of the V E I , i.e., VE against infectiousness or direct transmission to others. The summary measure is 54% (95% CI: 38 -66%), indicating the vaccination reduces the transmission to others by 54% when vaccinated people are infected, compared to unvaccinated people who become infected. Now we consider VE's for the variants of concern (VOC). Estimates are available for the V E SP , mostly after the first dose for the one dose vaccine and the second dose for the two dose vaccines. These estimates are given in Figure 9 (Tables A9-A11). For B.1.1.7, VE is 86% (95% CI: 65 -84%), which is just somewhat reduced compared to the wild type virus, but this VOC does not have a mutation that affects immunity. In contrast, the two other variants B.1.1.28 (P1) and B.1.351 have summary estimates of VE's of 61% (95% CI: 43 -73%) and 56% (95% CI: 29 -73%), respectively, that is considerably lower than the VE's for the wild type viruses. Both of these VOC's have mutations that affect immune function. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. We have presented the relevant VE estimates for the COVID-19 vaccines that are being rolled out on a global scale and for which there is sufficient quality data. We provide estimates of VE against disease with confirmed infection, infection, and transmission to others. The VE estimates against disease are stratified by disease severity, hospitalization and death. We have also provided VE estimates for three of the VOC. These estimates should be useful for constructing mathematical models for vaccination impact and for making policy decisions involving vaccination. We plan to keep updating this report as more information becomes available. 8 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.20.21257461 doi: medRxiv preprint For each vaccine efficacy measure (e.g., severe disease, infection), we first obtained log odds ratios and corresponding sampling variances from each vaccine efficacy estimate and 95% confidence interval (CI). We then fit random-effects models to these data to estimate average log odds ratios, which we back-transformed to obtain VE summary estimates and 95% CIs. All analyses were done in R version 4.0.2 using the package metafor (R Project for Statistical Computing) [2, 3] . This work was partially funded by NIH grants R01AI139761 and R56AI148284. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Here we give the details about the studies and data that are summarized in the figures. Note: indicates that the VE estimate is based on double-blinded, randomized trials. 10 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; 14 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.20.21257461 doi: medRxiv preprint 15 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.20.21257461 doi: medRxiv preprint h Measurement of vaccine effectiveness against asymptomatic infection with the potential to reduce asymp- . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.20.21257461 doi: medRxiv preprint tomatic transmission of the virus. i (V E I = 1 − 1 4 = 0.75) Estimated measurement of vaccine efficacy against transmission based on preliminary data from an observational study in Israel. According to a CDC Science Brief, the data from Israel "suggest that people vaccinated with Pfizer-BioNTech COVID-19 vaccine who develop COVID-19 have a four-fold lower viral load than unvaccinated people. This observation may indicate reduced transmissibility, as viral load has been identified as a key driver of transmision" [20, 26] . j According to Sadoff et al., "The analysis of vaccine efficacy against asymptomatic infection included all of the participants with a newly positive N-immunoassay result at day 71 (i.e., those who had been seronegative or had no result available at day 29 and who were seropositive at day 71). Only 2650 patients had an N-immunoassay result available at day 71, and therefore only a preliminary analysis could be performed. A total of 18 asymptomatic infections were identified in the vaccine group and 50 in the placebo group" [12] . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2021. ; 24 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.20.21257461 doi: medRxiv preprint Design and Analysis of Vaccine Studies Conducting Meta-Analyses in R with the metafor Package R: a language and environment for statistical computing Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 The Lancet Supply Vaccines to Eliminate Human Diseases Evidence Assessment: Sinopharm/bbibp Covid-19 Vaccine BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting Safety and Efficacy of Single-Dose Ad26. COV2. S Vaccine against Covid-19 Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia GRADE: Moderna COVID-19 Vaccine Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system Science Brief: Background Rationale and Evidence for Public Health Recommendations for Fully Vaccinated People Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening Interpreting vaccine efficacy trial results for infection and transmission. medRxiv Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared Decreased SARS-CoV-2 viral load following vaccination. medRxiv. 2021 New SARS-CoV-2 Variants -Clinical, Public Health, and Vaccine Implications Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B. 1.351 Variant Covid-19: Where are we on vaccines and variants How the different Covid vaccines will handle new variants of the virus. CNBC; 2021 Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: A test-negative case-control study. medRxiv Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant